MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing invariant natural killer T (iNKT) cell therapy platform-based product candidates. The company is investigating its iNKT cell therapies for conditions including graft-versus-host disease (GvHD), solid tumors, multiple myeloma, and acute respiratory distress syndrome (ARDS) secondary to COVID-19. MiNK operates in the adoptive cell therapy space and maintains a relationship with Agenus, which provides product liability insurance coverage for the company.
Q2 FY2026 — expected 2026-09-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134813 | EDGAR | 74K words |
| 2025-03-18 | 2024-12-31 | 0000950170-25-041379 | EDGAR | 67K words |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034672 | EDGAR | 68K words |
| 2023-03-24 | 2022-12-31 | 0000950170-23-009762 | EDGAR | 69K words |
| 2022-03-18 | 2021-12-31 | 0001564590-22-011026 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001193125-26-349309 | EDGAR | 14K words |
| 2025-11-14 | 2025-09-30 | 0001193125-25-282905 | EDGAR | 16K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108894 | EDGAR | 14K words |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072789 | EDGAR | 12K words |
| 2024-11-14 | 2024-09-30 | 0000950170-24-127033 | EDGAR | 14K words |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096142 | EDGAR | 13K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059081 | EDGAR | 12K words |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063851 | EDGAR | 13K words |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040958 | EDGAR | 12K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021191 | EDGAR | 11K words |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021565 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001564590-22-029503 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-13 | 0001193125-26-347907 | EDGAR | 2K words |
| 2026-03-31 | 0001193125-26-133346 | EDGAR | 1K words |
| 2026-03-27 | 0001193125-26-127931 | EDGAR | 1K words |
| 2026-03-19 | 0001193125-26-116219 | EDGAR | 1K words |
| 2026-01-02 | 0001193125-26-000916 | EDGAR | 1K words |
| 2025-12-08 | 0001193125-25-311229 | EDGAR | 6K words |
| 2025-09-29 | 0001193125-25-221863 | EDGAR | 1K words |
| 2025-08-14 | 0001171843-25-005405 | EDGAR | 1K words |
| 2025-07-15 | 0001193125-25-159017 | EDGAR | 21K words |
| 2025-07-14 | 0000950170-25-095460 | EDGAR | 1K words |
72 total filings indexed. 45 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001840229 |
| Ticker | INKT |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.minktherapeutics.com |
| Listed | 2021-10-15 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/INKT (~200 tokens, structured JSON with cryptographic provenance)